|
Lung cancer is the leading cause of cancer-related mortality
in the United States. Despite great advances in the understanding
of lung cancer biology, only 15% of patients are alive
five years after diagnosis. Our research program is designed
to understand thoracic cancer biology, discover novel agents,
and improve treatment.
Selected Clinical Research Protocols
- Phase III trial of carboplatin/ gemcitabine followed
by immediate or delayed docetaxel for patients
with advanced NSCLC
- A pilot study of early intervention with palliative
care in the treatment of patients with
advanced lung cancer
- Phase II study of C225 in patients with advanced lung
cancer
- Phase I/II study
of chemotherapy with dose-escalated IMRT for patients
with locally advanced NSCLC
- Phase I study of gefitinib and oral
vinorelbine in patients with advanced previously
treated NSCLC
- TARGET - Trial to Assess Response to Gefitinib in EGFR-mutated
Tumors
Read
more on clinical research in thoracic cancers.
|
